Financhill
Sell
17

OGI Quote, Financials, Valuation and Earnings

Last price:
$1.56
Seasonality move :
20.35%
Day range:
$1.44 - $1.61
52-week range:
$1.22 - $2.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.16x
P/B ratio:
0.87x
Volume:
1.1M
Avg. volume:
855.8K
1-year change:
27.87%
Market cap:
$196.8M
Revenue:
$117.5M
EPS (TTM):
-$0.41

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
OGI
OrganiGram Holdings
$31M -$0.04 27.69% -85.26% --
AUPH
Aurinia Pharmaceuticals
$57.7M $0.02 32.93% -24.07% --
EDSA
Edesa Biotech
-- -- -- -- $20.50
EPIX
ESSA Pharma
-- -$0.20 -- -28.8% --
LEXX
Lexaria Bioscience
$100K -- -31.04% -- --
XENE
Xenon Pharmaceuticals
-- -$0.79 -- -28.14% $57.67
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
OGI
OrganiGram Holdings
$1.56 -- $196.8M -- $0.00 0% 1.16x
AUPH
Aurinia Pharmaceuticals
$9.03 -- $1.3B -- $0.00 0% 5.92x
EDSA
Edesa Biotech
$1.65 $20.50 $5.7M -- $0.00 0% 16.05x
EPIX
ESSA Pharma
$1.60 -- $71M -- $0.00 0% --
LEXX
Lexaria Bioscience
$2.23 -- $38.9M -- $0.00 0% 59.30x
XENE
Xenon Pharmaceuticals
$38.69 $57.67 $2.9B -- $0.00 0% 222.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
OGI
OrganiGram Holdings
0.03% -0.288 0.03% 2.71x
AUPH
Aurinia Pharmaceuticals
-- 0.341 -- 4.90x
EDSA
Edesa Biotech
-- 0.099 -- --
EPIX
ESSA Pharma
-- 0.357 -- --
LEXX
Lexaria Bioscience
-- 5.584 -- 55.84x
XENE
Xenon Pharmaceuticals
-- 0.783 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
OGI
OrganiGram Holdings
$12.6M $207.4K -15.83% -15.83% 9.4% $5.1M
AUPH
Aurinia Pharmaceuticals
$61.7M $11.7M -5.99% -5.99% 23.63% $16.9M
EDSA
Edesa Biotech
-- -$967.2K -- -- -- -$967K
EPIX
ESSA Pharma
-- -$7M -- -- -- -$3.4M
LEXX
Lexaria Bioscience
$84K -$1.7M -93.31% -93.31% -2074.9% -$1.3M
XENE
Xenon Pharmaceuticals
-- -$73.7M -- -- -- -$51.7M

OrganiGram Holdings vs. Competitors

  • Which has Higher Returns OGI or AUPH?

    Aurinia Pharmaceuticals has a net margin of -12.16% compared to OrganiGram Holdings's net margin of 21.17%. OrganiGram Holdings's return on equity of -15.83% beat Aurinia Pharmaceuticals's return on equity of -5.99%.

    Company Gross Margin Earnings Per Share Invested Capital
    OGI
    OrganiGram Holdings
    38.52% -$0.07 $226.5M
    AUPH
    Aurinia Pharmaceuticals
    91.1% $0.10 $388M
  • What do Analysts Say About OGI or AUPH?

    OrganiGram Holdings has a consensus price target of --, signalling upside risk potential of 108.97%. On the other hand Aurinia Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 20%. Given that OrganiGram Holdings has higher upside potential than Aurinia Pharmaceuticals, analysts believe OrganiGram Holdings is more attractive than Aurinia Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    OGI
    OrganiGram Holdings
    4 2 0
    AUPH
    Aurinia Pharmaceuticals
    0 0 0
  • Is OGI or AUPH More Risky?

    OrganiGram Holdings has a beta of 1.019, which suggesting that the stock is 1.905% more volatile than S&P 500. In comparison Aurinia Pharmaceuticals has a beta of 1.408, suggesting its more volatile than the S&P 500 by 40.752%.

  • Which is a Better Dividend Stock OGI or AUPH?

    OrganiGram Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrganiGram Holdings pays -- of its earnings as a dividend. Aurinia Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OGI or AUPH?

    OrganiGram Holdings quarterly revenues are $32.8M, which are smaller than Aurinia Pharmaceuticals quarterly revenues of $67.8M. OrganiGram Holdings's net income of -$4M is lower than Aurinia Pharmaceuticals's net income of $14.4M. Notably, OrganiGram Holdings's price-to-earnings ratio is -- while Aurinia Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrganiGram Holdings is 1.16x versus 5.92x for Aurinia Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OGI
    OrganiGram Holdings
    1.16x -- $32.8M -$4M
    AUPH
    Aurinia Pharmaceuticals
    5.92x -- $67.8M $14.4M
  • Which has Higher Returns OGI or EDSA?

    Edesa Biotech has a net margin of -12.16% compared to OrganiGram Holdings's net margin of --. OrganiGram Holdings's return on equity of -15.83% beat Edesa Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    OGI
    OrganiGram Holdings
    38.52% -$0.07 $226.5M
    EDSA
    Edesa Biotech
    -- -$0.29 --
  • What do Analysts Say About OGI or EDSA?

    OrganiGram Holdings has a consensus price target of --, signalling upside risk potential of 108.97%. On the other hand Edesa Biotech has an analysts' consensus of $20.50 which suggests that it could grow by 1142.42%. Given that Edesa Biotech has higher upside potential than OrganiGram Holdings, analysts believe Edesa Biotech is more attractive than OrganiGram Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    OGI
    OrganiGram Holdings
    4 2 0
    EDSA
    Edesa Biotech
    0 0 0
  • Is OGI or EDSA More Risky?

    OrganiGram Holdings has a beta of 1.019, which suggesting that the stock is 1.905% more volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.837%.

  • Which is a Better Dividend Stock OGI or EDSA?

    OrganiGram Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrganiGram Holdings pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OGI or EDSA?

    OrganiGram Holdings quarterly revenues are $32.8M, which are larger than Edesa Biotech quarterly revenues of --. OrganiGram Holdings's net income of -$4M is lower than Edesa Biotech's net income of -$962.1K. Notably, OrganiGram Holdings's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrganiGram Holdings is 1.16x versus 16.05x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OGI
    OrganiGram Holdings
    1.16x -- $32.8M -$4M
    EDSA
    Edesa Biotech
    16.05x -- -- -$962.1K
  • Which has Higher Returns OGI or EPIX?

    ESSA Pharma has a net margin of -12.16% compared to OrganiGram Holdings's net margin of --. OrganiGram Holdings's return on equity of -15.83% beat ESSA Pharma's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    OGI
    OrganiGram Holdings
    38.52% -$0.07 $226.5M
    EPIX
    ESSA Pharma
    -- -$0.14 --
  • What do Analysts Say About OGI or EPIX?

    OrganiGram Holdings has a consensus price target of --, signalling upside risk potential of 108.97%. On the other hand ESSA Pharma has an analysts' consensus of -- which suggests that it could grow by 492.85%. Given that ESSA Pharma has higher upside potential than OrganiGram Holdings, analysts believe ESSA Pharma is more attractive than OrganiGram Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    OGI
    OrganiGram Holdings
    4 2 0
    EPIX
    ESSA Pharma
    0 0 0
  • Is OGI or EPIX More Risky?

    OrganiGram Holdings has a beta of 1.019, which suggesting that the stock is 1.905% more volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.624, suggesting its more volatile than the S&P 500 by 62.388%.

  • Which is a Better Dividend Stock OGI or EPIX?

    OrganiGram Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrganiGram Holdings pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OGI or EPIX?

    OrganiGram Holdings quarterly revenues are $32.8M, which are larger than ESSA Pharma quarterly revenues of --. OrganiGram Holdings's net income of -$4M is higher than ESSA Pharma's net income of -$6.4M. Notably, OrganiGram Holdings's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrganiGram Holdings is 1.16x versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OGI
    OrganiGram Holdings
    1.16x -- $32.8M -$4M
    EPIX
    ESSA Pharma
    -- -- -- -$6.4M
  • Which has Higher Returns OGI or LEXX?

    Lexaria Bioscience has a net margin of -12.16% compared to OrganiGram Holdings's net margin of -2121.06%. OrganiGram Holdings's return on equity of -15.83% beat Lexaria Bioscience's return on equity of -93.31%.

    Company Gross Margin Earnings Per Share Invested Capital
    OGI
    OrganiGram Holdings
    38.52% -$0.07 $226.5M
    LEXX
    Lexaria Bioscience
    -- -$0.13 $9.7M
  • What do Analysts Say About OGI or LEXX?

    OrganiGram Holdings has a consensus price target of --, signalling upside risk potential of 108.97%. On the other hand Lexaria Bioscience has an analysts' consensus of -- which suggests that it could grow by 348.43%. Given that Lexaria Bioscience has higher upside potential than OrganiGram Holdings, analysts believe Lexaria Bioscience is more attractive than OrganiGram Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    OGI
    OrganiGram Holdings
    4 2 0
    LEXX
    Lexaria Bioscience
    0 0 0
  • Is OGI or LEXX More Risky?

    OrganiGram Holdings has a beta of 1.019, which suggesting that the stock is 1.905% more volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.234%.

  • Which is a Better Dividend Stock OGI or LEXX?

    OrganiGram Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrganiGram Holdings pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OGI or LEXX?

    OrganiGram Holdings quarterly revenues are $32.8M, which are larger than Lexaria Bioscience quarterly revenues of $84K. OrganiGram Holdings's net income of -$4M is lower than Lexaria Bioscience's net income of -$1.8M. Notably, OrganiGram Holdings's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrganiGram Holdings is 1.16x versus 59.30x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OGI
    OrganiGram Holdings
    1.16x -- $32.8M -$4M
    LEXX
    Lexaria Bioscience
    59.30x -- $84K -$1.8M
  • Which has Higher Returns OGI or XENE?

    Xenon Pharmaceuticals has a net margin of -12.16% compared to OrganiGram Holdings's net margin of --. OrganiGram Holdings's return on equity of -15.83% beat Xenon Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    OGI
    OrganiGram Holdings
    38.52% -$0.07 $226.5M
    XENE
    Xenon Pharmaceuticals
    -- -$0.81 --
  • What do Analysts Say About OGI or XENE?

    OrganiGram Holdings has a consensus price target of --, signalling upside risk potential of 108.97%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.67 which suggests that it could grow by 49.05%. Given that OrganiGram Holdings has higher upside potential than Xenon Pharmaceuticals, analysts believe OrganiGram Holdings is more attractive than Xenon Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    OGI
    OrganiGram Holdings
    4 2 0
    XENE
    Xenon Pharmaceuticals
    11 0 0
  • Is OGI or XENE More Risky?

    OrganiGram Holdings has a beta of 1.019, which suggesting that the stock is 1.905% more volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.189, suggesting its more volatile than the S&P 500 by 18.926%.

  • Which is a Better Dividend Stock OGI or XENE?

    OrganiGram Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrganiGram Holdings pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OGI or XENE?

    OrganiGram Holdings quarterly revenues are $32.8M, which are larger than Xenon Pharmaceuticals quarterly revenues of --. OrganiGram Holdings's net income of -$4M is higher than Xenon Pharmaceuticals's net income of -$62.8M. Notably, OrganiGram Holdings's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrganiGram Holdings is 1.16x versus 222.63x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OGI
    OrganiGram Holdings
    1.16x -- $32.8M -$4M
    XENE
    Xenon Pharmaceuticals
    222.63x -- -- -$62.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 21

Quantum [QMCO] is up 26.28% over the past day.

Sell
46
NUKK alert for Dec 21

Nukkleus [NUKK] is down 22.94% over the past day.

Sell
1
IIPR alert for Dec 21

Innovative Industrial Properties [IIPR] is down 22.7% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock